Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
48
Participants
Timeline
Start Date
March 1, 2024
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
Conditions
Atrial Fibrillation
Interventions
DRUG
SHR-2004 injection
dose 1 or dose 2 or dose 3 or dose 4 or dose 5 or dose 6
All Listed Sponsors
lead
Beijing Suncadia Pharmaceuticals Co., Ltd
INDUSTRY
NCT06280768 - Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation | Biotech Hunter | Biotech Hunter